Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb


UCB FY Consensus Product Sales Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,877 1,958 1,976 1,828 1,540 1,340   5,153
Vimpat 1,451 1,542 1,125 747 599 515 422   2,209
Keppra  788 754 682 623 575 534 484   2,236
Briviact 288 352 424 488 544 585 572 632 1,909
Neupro 311 276 235 205 178 155 146   573
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   518 682 825 954 1,055 1,174 1,329 2,186
Nayzilam 26  50 73 96 117 129 134 165 376
Bimekizumab   97 360 708 1,095 1,494 1,744 2,554 6,184
Zilucoplan   0 11 133 303 497 683 1,162 2,202
Rozanolixizumab    0 11 81 199 355 468 928 1,700
Dapimab   7 16 34 57 110 120    
Staccato alprazolam   0 0 2 23 74 86 270 395
UCB0107 (Anti-Tau)   0 0 0 37 92 148    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052   5,339  5,264  5,325 5,604  5,801 
Revenue 5,347   5,576 5,495  5,548  5,820  6,026 
Adjusted EBIT 1,093   1,206 1,251  1,312  1,492   1,611
Adjusted EBITDA 1,441   1,561 1,602  1,676  1,864  1,984 
Net Profit*  732  911  948  1,015  1,173  1,296 
Core EPS (€) 5.36  5.74 5.89 6.33 7.16  7.79 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,890 1,996 1,965 1,832 1,522 1,327   4,971
Vimpat 1,451 1,532 1,061 647 561 495 421   2,406
Keppra 788 744 680 625 580 535 475   1,992
Briviact 288 346 421 485 542 590 565 626 1,684
Neupro 311 280 238 198 166 146 144   537
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   504 682 824 947 1,038 1,145 1,281 1,975
Nayzilam  26 48 70 90 116 130 134 150 409
Bimekizumab   78 340 700 1,048 1,443 1,747 2,618 5,923
Zilucoplan   0 0 140 302 463 591 1,137 2,069
Rozanolixizumab (Rozimab)   0 0 75 175 344 492 925 1,578
Dapimab   0 0 0 0 50 113    
Staccato alprazolam   0 0 0 23 65 82 200 420
UCB0107 (Anti-Tau)   0 0 0 3 53 45    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052  5,324  5,202  5,320  5,667   5,790
Revenue 5,347  5,578  5,416   5,520 5,888  6,000 
Adjusted EBIT 1,093  1,194  1,254  1,334  1,467  1,638 
Adjusted EBITDA 1,441  1,550  1,646  1,684  1,857   2,027
Net Profit*  732  908  951  986  1,155  1,307 
Core EPS (€) 5.36  5.72  5.93  6.38  7.08  7.97 

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 15 March 2021



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.